VALID TRIAL
Both CHIA and your personal trial have the following criteria:
╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                  │ CHIA Criteria                                      │   Score │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ Women must be postmenopausal (i.e.12 months        │ Women must be postmenopausal (i.e.12 months        │     100 │
│ without menstrual period), or surgically sterile,  │ without menstrual period), or surgically sterile,  │         │
│ i.e. women of child bearing potential are not      │ i.e. women of child bearing potential are not      │         │
│ allowed to be included into the study. In cases of │ allowed to be included into the study. In cases of │         │
│ doubt a pregnancy test should be performed. (NB    │ doubt a pregnancy test should be performed. (NB    │         │
│ -post menopausal women currently receiving hormone │ -post menopausal women currently receiving hormone │         │
│ replacement are permissible)                       │ replacement are permissible)                       │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ ST elevation in 2 contiguous ECG leads (= 2 mm     │ ST elevation in 2 contiguous ECG leads (= 2 mm     │     100 │
│ precordial lead, = 1 mm limb lead). This ECG       │ precordial lead, = 1 mm limb lead). This ECG       │         │
│ recording serves as baseline ECG, i.e. ECG I       │ recording serves as baseline ECG, i.e. ECG I       │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Planned primary percutaneous coronary intervention │ Planned primary percutaneous coronary intervention │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ The subject has given written informed, dated      │ The subject has given written informed, dated      │     100 │
│ consent to participate in the study                │ consent to participate in the study                │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Subjects not able to give informed consent         │ Subjects not able to give informed consent         │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Left Bundle Branch Block                           │ Left Bundle Branch Block                           │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Thrombolytic therapy within 24 hours before        │ Thrombolytic therapy within 24 hours before        │     100 │
│ randomization                                      │ randomization                                      │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Stroke or Transient Ischemic Attack (TIA) within   │ Stroke or Transient Ischemic Attack (TIA) within   │     100 │
│ the past 6 months or any permanent residual        │ the past 6 months or any permanent residual        │         │
│ neurological defect                                │ neurological defect                                │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Evidence of an active gastrointestinal or          │ Evidence of an active gastrointestinal or          │     100 │
│ urogenital bleeding                                │ urogenital bleeding                                │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Major surgery within 6 weeks                       │ Major surgery within 6 weeks                       │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ History of allergic reaction to abciximab or       │ History of allergic reaction to abciximab or       │     100 │
│ eptifibatide or any component used in the study    │ eptifibatide or any component used in the study    │         │
│ (including contrast media)                         │ (including contrast media)                         │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Known severe renal (creatinine clearance           │ Known severe renal (creatinine clearance           │     100 │
│ \<30ml/min) or hepatic insufficiency as well as    │ <30ml/min) or hepatic insufficiency as well as     │         │
│ Alanine transaminase (ALT)/aspartate transaminase  │ Alanine transaminase (ALT)/aspartate transaminase  │         │
│ (AST) elevations = 3xUpper limit normal (ULN);     │ (AST) elevations = 3xUpper limit normal (ULN);     │         │
│ isolated AST-elevation is not considered an        │ isolated AST-elevation is not considered an        │         │
│ exclusion criteria from study participation        │ exclusion criteria from study participation        │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Subject has participated in any study using an     │ Subject has participated in any study using an     │     100 │
│ investigational drug or device within 30 days or   │ investigational drug or device within 30 days or   │         │
│ within 5 half-lives of the investigational drug    │ within 5 half-lives of the investigational drug    │         │
│ (whichever is longer) of entry into this study     │ (whichever is longer) of entry into this study     │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Subjects who will be inaccessible due to           │ Subjects who will be inaccessible due to           │     100 │
│ geographic or social factors during treatment or   │ geographic or social factors during treatment or   │         │
│ follow-up                                          │ follow-up                                          │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ In France, a subject is neither affiliated with    │ In France, a subject is neither affiliated with    │     100 │
│ nor a beneficiary of a social security category    │ nor a beneficiary of a social security category    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Acute myocardial infarction \< 12 h defined as     │ Acute myocardial infarction < 12 h defined as      │      99 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Angina or equivalent symptoms \> 20 min and        │ Angina or equivalent symptoms > 20 min and         │      99 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Oral anticoagulation with International Normalized │ Oral anticoagulation with International Normalized │      99 │
│ Ratio (INR) \> 2                                   │ Ratio (INR) > 2                                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Known platelets \< 100.000/µl or known hemorrhagic │ Known platelets < 100.000/µl or known hemorrhagic  │      99 │
│ diathesis                                          │ diathesis                                          │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Severe concomitant disease with life expectation   │ Severe concomitant disease with life expectation < │      99 │
│ \< 1 year                                          │ 1 year                                             │         │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

Only your personal trial has the following criteria:
╒═══════════════════════════════════╤════════════════════════════════════════════╤═════════╕
│ Personal Criteria                 │ CHIA Criteria                              │   Score │
╞═══════════════════════════════════╪════════════════════════════════════════════╪═════════╡
│ Must have minimum age of 18 Years │ Subjects not able to give informed consent │      40 │
╘═══════════════════════════════════╧════════════════════════════════════════════╧═════════╛

CHIA has no unique criteria

Levenshtein Ratio of Entire trial at once: 99
Average Levenshtein Ratio of individual lines: 96.9047619047619
OverAll Ratio: 97.95238095238095
